Exero Medical

Exero Medical develops a biodegradable wireless sensor for early detection of anastomotic leaks following GI surgery. The system is designed to prevent complications by warning physicians of potential leaks, allowing early intervention. Anastomotic leaks are a common, life-threatening complication of GI surgeries, such as colorectal and bariatric surgeries. Early detection before the clinical manifestation of an anastomotic leak is key to a favorable outcome, but diagnosis at this stage is difficult. This delay in diagnosis affects both mortality rates and economic burdens. Exero Medicals system deploys a sensor that continuously monitors the condition of the anastomosis area, enabling early detection and preventive action before the patients condition deteriorates. In December 2020, the FDA granted breakthrough device designation for Exero Medicals wireless system designed for the early detection of potentially lethal anastomotic leaks following gastrointestinal surgery.

Exero Medical has raised $16.1M in total funding across 5 rounds. The company is currently at the Seed stage. Key investors include Tech Council Ventures, Longevity Venture Partners, Edge Medical Ventures.

Exero Medical was founded in 2018 by Matan BenDavid (Founder).

Exero Medical operates in Health Tech & Life Sciences, Medical Devices, Medical Monitors, Digital Healthcare, Patient Remote Monitoring, with core technologies in Sensing, Materials & Substances, Implants. Target customers: Healthcare & Life Sciences, Healthcare, Providers.

Exero Medical is based in Ariel Sharon Boulevard 8, Or Yehuda, Israel, Center District.